Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD

SUMMARY Cell replacement therapies for Parkinson’s disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design. The STEM-PD product was manufactured under GMP and quality tested in vitro and in vivo to meet regulatory requirements. Importantly, no adverse effects were observed upon testing of the product in a 39-week rat GLP safety study for toxicity, tumorigenicity, and biodistribution, and a non-GLP efficacy study confirmed that the transplanted cells mediated full functional recovery in a pre-clinical rat model of PD. We further observed highly comparable efficacy results between two different GMP batches, verifying that the product can be serially manufactured. A fully in vivo-tested batch of STEM-PD is now being used in a clinical trial of 8 patients with moderate PD, initiated in 2022.

[1]  Sang-Hun Lee,et al.  Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Tabar,et al.  Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. , 2021, Cell stem cell.

[3]  M. Tomishima,et al.  Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. , 2021, Cell stem cell.

[4]  G. Petsko,et al.  Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. , 2020, The New England journal of medicine.

[5]  J. Takahashi.  iPS cell-based therapy for Parkinson's disease: A Kyoto trial , 2020, Regenerative therapy.

[6]  S. Lazic,et al.  Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease , 2019, Nature Medicine.

[7]  D. Brooks,et al.  Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs , 2018, Experimental Neurology.

[8]  J. Sørensen,et al.  Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway , 2018, Brain Research Bulletin.

[9]  A. Heuer,et al.  Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation , 2017, Nature Protocols.

[10]  Aage Kristian Olsen Alstrup,et al.  A fiducial skull marker for precise MRI-based stereotaxic surgery in large animal models , 2017, Journal of Neuroscience Methods.

[11]  S. Dunnett,et al.  Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson’s Disease , 2017, Cell stem cell.

[12]  A. Björklund,et al.  Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain , 2016, Proceedings of the National Academy of Sciences.

[13]  A. Björklund,et al.  Monosynaptic Tracing using Modified Rabies Virus Reveals Early and Extensive Circuit Integration of Human Embryonic Stem Cell-Derived Neurons , 2015, Stem cell reports.

[14]  A. Björklund,et al.  Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease , 2014, Cell stem cell.

[15]  A. Papazoglou,et al.  Survival and Functional Restoration of Human Fetal Ventral Mesencephalon following Transplantation in a Rat Model of Parkinson's Disease , 2013, Cell transplantation.

[16]  Roger A. Barker,et al.  Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.

[17]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[18]  O. Lindvall,et al.  Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Webber.  Center , 2011 .

[20]  O. Lindvall,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[21]  Stanley Fahn,et al.  Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes , 2010, Journal of Nuclear Medicine.

[22]  M. Tomishima,et al.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.

[23]  A. Björklund,et al.  Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. , 2005, Brain : a journal of neurology.

[24]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[25]  M. Horne,et al.  Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei , 2002, The Journal of comparative neurology.

[26]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[27]  C. Goetz,et al.  Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery , 1997, Experimental Neurology.

[28]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[29]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[30]  B J Hoffer,et al.  Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.

[31]  A. Björklund,et al.  Restorative cell and gene therapies for Parkinson's disease. , 2023, Handbook of clinical neurology.

[32]  R. Barker,et al.  Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). , 2017, Progress in brain research.

[33]  A. Björklund,et al.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.

[34]  H. Onoe,et al.  Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. , 2011, Journal of Parkinson's disease.

[35]  Lieberman,et al.  The evolution and origin of motor complications in Parkinson's disease. , 2000, Neurology.

[36]  T. Ganesh,et al.  News and Events , 1987, IEEE Circuits and Devices Magazine.